Some say that including yogurt in our diets could help keep diabetes at bay, a claim that gets no objection from the FDA. A nutritionist weighs in on the benefits.
Can incorporating yogurt into your diet keep diabetes at bay? The U.S. Food and Drug Administration has implied that it’s possible. The health agency announced in March that it will not object to a claim from Danone North America — maker of Dannon and other popular yogurt brands — that regularly eating yogurt could reduce the risk of type 2 diabetes.
The FDA intends to allow the claim to appear on yogurt food labels, 'provided that the qualified health claims are worded so as not to mislead consumers, and that other factors for the use of the claim are met.
Regular consumption is considered 2 cups per week of yogurt, which is the minimum amount for this qualified health claim. 'I don't like the idea of suggesting that one food alone has the power to reduce disease, because we know it's really all about the pattern of eating,' she told Fox News Digital.
There's likely no additional benefit beyond a couple of servings, Collins said. Fox News Digital reached out to Danone requesting comment. For more Health articles, visit www.foxnews.com/health.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How eating ‘bacon bugs’ helps save lemursA National Geographic Explorer is betting on the tasty and nutritious insects as an alternate food source to the meat of Madagascar's endangered primates.
Read more »
Many cancer drugs remain unproven years after FDA's accelerated approval, study findsThe FDA's accelerated approval program is meant to give patients early access to promising drugs, but a new study found most cancer drugs do not demonstrate benefits within five years.
Read more »
Study Finds Limited Clinical Benefit for Cancer Drugs Approved Under FDA's Accelerated Approval PathwayA new study reveals that less than half of the cancer drugs approved under the FDA's accelerated approval pathway have been shown to improve overall survival or quality of life, despite being on the market for more than 5 years.
Read more »
Most Cancer Drugs Granted Accelerated Approval by FDA Do Not Show Benefits Within Five YearsA new study reveals that the majority of cancer drugs granted accelerated approval by the FDA do not demonstrate benefits within five years.
Read more »
FDA Expands Enhertu Indication to HER2-Positive Solid TumorsThe move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.
Read more »
FDA Expands Approval of Fam-Trastuzumab-Deruxtecan-Nxki for HER2-Positive Gastric CancerThe US Food and Drug Administration (FDA) has expanded the approval of fam-trastuzumab–deruxtecan-nxki (Enhertu; AstraZeneca and Daiichi Sankyo, Inc) to adults with unresectable or metastatic as well as adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had received a prior trastuzumab-based regimen. This approval provides a new treatment option for patients with limited options.
Read more »